Psoriatic Arthritis | Emerging Therapies | Xeljanz (tofacitinib) Psoriatic Arthritis - Wave 3 (US)

Publish date: February 2019

Login to access report

Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA) and the only other oral targeted therapy besides Celgene’s PDE-4 inhibitor, Otezla, approved for this indication. In recent years, multiple new therapies have been approved for the treatment of PsA. However, Xeljanz’s unique MOA, oral administration, and strong efficacy warrant the attention of both rheumatologists and dermatologists. The Emerging Therapy series in psoriatic arthritis includes three waves that will track the awareness, trial, and usage of Xeljanz since its approval in December 2017 for the treatment of PsA. In addition, the series will examine physician-anticipated future trends in PsA treatment, particularly Xeljanz’s uptake, as well as assess Pfizer’s promotional efforts.

QUESTIONS ANSWERED

  •  What is the awareness of, familiarity with, and perceptions related to Xeljanz among U.S. rheumatologists and dermatologists?
  • Among prescribers, for which patients are they prescribing Xeljanz, what are the reasons for prescribing, and how satisfied are they with Xeljanz?
  • How do prescribers and nonprescribers compare across key metrics?
  • How is the trial and adoption of Xeljanz tracking compared to other recent product launches in the autoimmune market?

PRODUCT DESCRIPTION

Emerging Therapies captures U.S. physicians’ awareness, perceptions, and usage of the launched product at one, six, and twelve months postlaunch, as well as the current and future impact on competitor therapies and the overall market. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, benchmarking against other launched agents, along with statistical comparative analysis with prior waves so that marketers can track and optimize the effectiveness of their launch strategy or fine-tune their product positioning to counter its impact on their brand’s share.

Table of contents

  • Xeljanz (tofacitinib) Psoriatic Arthritis - Wave 3 (US)
    • Psoriatic Arthritis Emerging Therapies Xeljanz US Wave 3 (March 2019)

Author(s): Elena Kozhemyakina, PhD; Colleen E. Albacker, PhD

Elena Kozhemyakina, PhD, is a Senior Business Insight Analyst at Decision Resources, Inc., specializing in pharmaceutical market analysis of the immune system disorders with expertise in Systemic Lupus Erythematosus, asthma, Crohn’s disease and ulcerative colitis. Prior to joining Decision Resources, Dr. Kozhemyakina completed a postdoctoral fellowship at Harvard Medical School, where she investigated molecular mechanisms involved in limb patterning, cartilage formation and pathogenesis of osteoarthritis. She published multiple peer-reviewed papers focused on molecular signalling of developmental disorders.

Colleen E. Albacker, is a director with the Immune and Inflammatory Disorders group at Decision Resources Group, where she comanages a team of analysts generating syndicated market research content. She has authored market research reports analyzing physician, payer, and market trends in respiratory indications, including asthma and COPD. Prior to joining Decision Resources Group, Dr. Albacker conducted her graduate research on chromatin-modifying factors in zebrafish cancer and hematopoietic development at Harvard Medical School and Boston Children’s Hospital. She also gained experience with market research through a fellowship with the Harvard Office of Technology Development. Dr. Albacker holds a in genetics from Harvard University and a in biology with honors from the Pennsylvania State University.